Latest Conference Articles

December 6th 2016, 7:19pm

ASH Annual Meeting and Exposition

Subcutaneous delivery of daratumumab was well tolerated with comparable efficacy to the FDA-approved intravenous dose in patients with relapsed/refractory multiple myeloma.

December 6th 2016, 2:13pm

ASH Annual Meeting and Exposition

Adding venetoclax to bortezomib and dexamethasone showed very promising efficacy and acceptable safety for patients with relapsed/refractory multiple myeloma.

December 6th 2016, 7:19am

ASH Annual Meeting and Exposition

Selinexor, in combination with dexamethasone, induced a response rate of 20.5% (n = 16) among 78 heavily pretreated patients with relapsed/refractory multiple myeloma, according to results from the phase IIb STORM trial presented at the 2016 ASH Annual Meeting.

December 6th 2016, 6:31am

ASH Annual Meeting and Exposition

Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.

December 6th 2016, 5:03am

ASH Annual Meeting and Exposition

Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma.

December 6th 2016, 3:24am

IASLC World Conference on Lung Cancer

Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.

December 6th 2016, 3:11am

ASH Annual Meeting and Exposition

Adding the oral BCL-2 inhibitor venetoclax (Venclexta) to obinutuzumab (Gazyva) and ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia is safe and is demonstrating encouraging signs of efficacy.

December 6th 2016, 1:50am

ASH Annual Meeting and Exposition

An induction regimen of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia.

December 6th 2016, 1:46am

ASH Annual Meeting and Exposition

Treatment with the BTK inhibitor BGB-3111 had an objective response rate of 96% for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

December 6th 2016, 1:17am

ASH Annual Meeting and Exposition

The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).

December 6th 2016, 12:02am

IASLC World Conference on Lung Cancer

Treatment with first-line avelumab yielded promising clinical benefit and durable antitumor activity in patients with advanced non–small cell lung cancer.

December 5th 2016, 11:30pm

ASH Annual Meeting and Exposition

The combination of the PI3 kinase inhibitor TGR-1202 and ibrutinib demonstrated a high response rate without dose-limiting toxicities for patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

December 5th 2016, 10:56pm

IASLC World Conference on Lung Cancer

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the rationale behind the development of a novel risk-prediction algorithm in the context of screening patients for lung cancer. He discussed this during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 5th 2016, 10:27pm

IASLC World Conference on Lung Cancer

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses the LuCED test, a non-invasive tool used to detect early stage lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

December 5th 2016, 10:24pm

IASLC World Conference on Lung Cancer

While treatment with nivolumab (Opdivo) significantly improved overall survival over docetaxel in patients with advanced non–small cell lung cancer in the CheckMate-057 trial, an analysis of deaths occurring within 3 months of initiation of therapy showed numerically more deaths in the nivolumab arm.

December 5th 2016, 8:08pm

IASLC World Conference on Lung Cancer

Douglas Arenberg, MD, discusses preliminary findings of a screening study, and the critical importance of maintaining quality tobacco cessation practices in healthcare clinics.

December 5th 2016, 9:06am

ASH Annual Meeting and Exposition

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.

December 5th 2016, 8:26am

ASH Annual Meeting and Exposition

Combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.

December 5th 2016, 8:24am

ASH Annual Meeting and Exposition

Treatment with the combination of pembrolizumab, pomalidomide, and dexamethasone demonstrated promising durable efficacy and a tolerable safety profile for patients with relapsed/refractory multiple myeloma.

December 5th 2016, 7:26am

ASH Annual Meeting and Exposition

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.